-DOCSTART- -X- O
Viral -X- _ O
diseases -X- _ O
affect -X- _ O
hundreds -X- _ O
of -X- _ O
millions -X- _ O
of -X- _ O
people -X- _ O
worldwide -X- _ O
, -X- _ O
and -X- _ O
the -X- _ O
few -X- _ O
available -X- _ O
drugs -X- _ O
to -X- _ O
treat -X- _ O
these -X- _ O
diseases -X- _ O
often -X- _ O
come -X- _ O
with -X- _ O
limitations. -X- _ O
The -X- _ O
key -X- _ O
obstacle -X- _ O
to -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
new -X- _ O
antiviral -X- _ O
agents -X- _ O
is -X- _ O
their -X- _ O
delivery -X- _ O
into -X- _ O
infected -X- _ O
cells -X- _ O
in -X- _ O
vivo. -X- _ O
Cell-penetrating -X- _ B-Intervention
peptides -X- _ I-Intervention
( -X- _ I-Intervention
CPPs -X- _ I-Intervention
) -X- _ I-Intervention
are -X- _ O
short -X- _ O
peptides -X- _ O
that -X- _ O
can -X- _ O
cross -X- _ O
the -X- _ O
cellular -X- _ O
lipid -X- _ O
bilayer -X- _ O
with -X- _ O
the -X- _ O
remarkable -X- _ O
capability -X- _ O
to -X- _ O
shuttle -X- _ O
conjugated -X- _ O
cargoes -X- _ O
into -X- _ O
cells. -X- _ O
CPPs -X- _ O
have -X- _ O
been -X- _ O
successfully -X- _ O
utilized -X- _ O
to -X- _ O
enhance -X- _ B-Outcome
the -X- _ I-Outcome
cellular -X- _ I-Outcome
uptake -X- _ I-Outcome
and -X- _ I-Outcome
intracellular -X- _ I-Outcome
trafficking -X- _ I-Outcome
of -X- _ I-Outcome
antiviral -X- _ I-Outcome
molecules -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
thereby -X- _ I-Outcome
increase -X- _ I-Outcome
the -X- _ I-Outcome
inhibitory -X- _ I-Outcome
activity -X- _ I-Outcome
of -X- _ I-Outcome
potential -X- _ I-Outcome
antiviral -X- _ I-Outcome
proteins -X- _ I-Outcome
and -X- _ I-Outcome
oligonucleotide -X- _ I-Outcome
analogues -X- _ I-Outcome
, -X- _ I-Outcome
both -X- _ I-Outcome
in -X- _ I-Outcome
cultured -X- _ I-Outcome
cells -X- _ I-Outcome
and -X- _ I-Outcome
in -X- _ I-Outcome
animal -X- _ I-Outcome
models. -X- _ I-Outcome
This -X- _ O
review -X- _ O
will -X- _ O
address -X- _ O
the -X- _ O
notable -X- _ O
findings -X- _ O
of -X- _ O
these -X- _ O
studies -X- _ O
, -X- _ O
highlighting -X- _ O
some -X- _ O
promising -X- _ O
results -X- _ O
and -X- _ O
discussing -X- _ O
the -X- _ O
challenges -X- _ O
CPP -X- _ O
technology -X- _ O
has -X- _ O
to -X- _ O
overcome -X- _ O
for -X- _ O
further -X- _ O
clinical -X- _ O
applications -X- _ O
. -X- _ O

